Products
-
- BBB DamageCell Death and ApoptosisNeuroinflammationNeuronal Damage and RepairOxidative StressVascular Mechanisms
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
Chrysamine G Disodium Salt (AC190)
Cat.#: ASSD-190
Specifications
Description Chrysamine G, a lipophilic derivative and carboxylic acid analog of Congo red (sc-359843), has been shown to bind to the β-amyloid protein in vitro. Synonyms .I. Direct Yellow 1; C.I. Direct Yellow 1, Disodium Salt; Chrysamine; Brasilamina Yellow G; C.I. 22250; Chrysamine A Size 10 mg, 25 mg Molecule Weight 526.41 Molecular formula C26H16N4Na2O6 CAS Number 6472-91-9 MDL Number MFCD07186299 Solubility Soluble in DMSO (1 mg/ml). Storage Store at 4° C Shipping Shipped at 4°C Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Size Price ASSD-191 Fluorescein 6-Isothiocyanate, Isomer 2, 95% (AC191) 100 mg inquiry ASSD-212 5(6)-Carboxy-2′,7′-dichlorofluorescein diacetate N-succinimidyl ester (AC212) 25 mg inquiry ASSD-224 Antifade Fluorescence Mounting Medium with DAPI (aqueous) (AC224) 10 mL inquiry ASSD-104 Hoechst 33258 (AC104) 25 mg, 100 mg inquiry ASSD-228 ImmunoHistoMount (AC228) 30 ml inquiry ASSD-127 Fluorescent H3 antagonist [clobenpropit] (AC127) 50 μg inquiry ASSD-189 7-Hydroxycoumarin-3-carboxylic acid (AC189) 100 mg inquiry ASSD-204 7-Diethylamino-3-[N-(2-maleimidoethyl)carbamoyl]coumarin (AC204) 1 mg, 5 mg inquiry ASSD-209 Tetramethylrhodamine isothiocyanate Isomer R (AC209) 5 mg, 10 mg inquiry ASSD-130 Calcein-AM (AC130) 1 mg inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
0Inquiry Basket